PHR vs HCAT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 21, 2026

PHR

46.3
AI Score
VS
HCAT Wins

HCAT

55.5
AI Score

Investment Advisor Scores

PHR

46score
Recommendation
HOLD

HCAT

56score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PHR HCAT Winner
Revenue 130.94M 141.24M HCAT
Net Income 2.96M -151.56M PHR
Net Margin 2.3% -107.3% PHR
Operating Income 6.75M -142.96M PHR
ROE 0.8% -150.3% PHR
ROA 0.4% -42.3% PHR
Total Assets 666.14M 358.60M PHR
Debt/Equity 0.00 1.52 PHR
Current Ratio 1.76 2.70 HCAT
Free Cash Flow 19.61M 18.10M PHR

Relative Price Performance (Last 90 Days)

PHR 1M: +23.7% · 3M: +38.0% HCAT 1M: -23.9% · 3M: +18.6%

Current Technical Phase

PHR

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (9.5% over 20 days), RSI 59

RSI (14): 59.3 · Price: $12.12

HCAT

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 32

RSI (14): 32.4 · Price: $1.53

Fundamentals Snapshot

Metric PHR HCAT
Market Cap
Forward P/E 8.0 38.4
Trailing P/E 70.4
Revenue (TTM)
Revenue Growth 0.1% -0.1%
Gross Margin 0.7% 0.5%
Operating Margin 0.1% -0.1%
EPS 0.17 -3.54
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HCAT is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.